For patients with newly diagnosed unmutated CLL how will you decide between BTKi alone vs Ven/BTKi vs Ven/Obin vs Ven/Obin/Acalabrutinib?

My usual practice has been Ven Obin for most patients, even unmutated, but if they have bulky nodes and are young/fit, I am now adding acala to that and giving the 3-drug regimen. Continuous BTKi in my practice is mostly reserved for the older or less fit patients, or those who really, really don’t ...

In the absence of head-to-head, prospective trial data (which we will soon see with ongoing trials such as MAJIC comparing AV and VenO + MRD-guided duration of therapy), we must fall back on our precautionary principles and try to minimize risk for patients while maximizing benefits. This means havi...

First, as with all CLL patients, we would discuss the benefits and risks of fixed-duration vs continuous BTKi therapy, here with the likelihood that fixed duration treatment might have shorter remission durations after initial treatment, but with the unknown duration of response with retreatment. If...